Clinical Trial Update: Ranibizumab for Neovascularization in Sickle Cell Retinopathy [NA]

View source ↗

Summary

A clinical trial evaluating ranibizumab for neovascularization in sickle cell retinopathy sponsored by Kresge Eye Institute has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Sickle Cell Retinopathy

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Kresge Eye Institute | Conditions: Sickle Cell Anemia, Retinopathy | NA | Status: WITHDRAWN